Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-NODAGA-E[c(RGDyK)]2 PET for Angiogenesis in Ischemic Heart Disease
NCT03505346Phase 2Not yet recruiting
- Sponsor
- Rigshospitalet
- Start
- Jan 2024
- Primary completion
- Dec 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of 68Ga-NODAGA-E(c[RGDyK])2 in chronic ischemic heart disease (CIHD), sponsored by Rigshospitalet. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
68Ga-NODAGA-E(c[RGDyK])2
03
Conditions
chronic ischemic heart disease (CIHD)
Beyond the preview
Go deeper on NCT03505346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03505346.